Puma Biotechnology (PBYI) Net Cash Flow (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Net Cash Flow data on file, last reported at $6.6 million in Q1 2026.

• Quarterly Net Cash Flow rose 205.96% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.8 million (down 95.59% YoY) and the FY2025 annual result came in at -$39.6 million, down 157.61% from the prior year.
• Net Cash Flow advanced to $6.6 million in Q1 2026, from -$23.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $25.2 million in Q3 2022 to a low of -$23.9 million in Q4 2025.
• A 5-year average of -$2.2 million and a median of -$1.8 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow surged 229.9% — and 2025, when it sank 1321.37%.
• Tracing PBYI's Net Cash Flow over 5 years: stood at -$1.8 million in 2022, then surged by 229.9% to $2.3 million in 2023, then slipped by 14.4% to $2.0 million in 2024, then slumped by 1321.37% to -$23.9 million in 2025, then jumped by 127.45% to $6.6 million in 2026.
• The last three Net Cash Flow figures came in at $6.6 million (Q1 2026), -$23.9 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.